MNA
NBIX icon

Manning & Napier Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Manning & Napier Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.35K Buy
55
+53
+2,650% +$7.86K ﹤0.01% 516
2026
Q1 		$257 Sell
2
-20
-91% -$2.65K ﹤0.01% 604
2025
Q4 		$3.1K Buy
+22
New +$3.19K ﹤0.01% 474

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Manning & Napier Advisors's NBIX Position: Q2 2026 in Review

Manning & Napier Advisors increased its Neurocrine Biosciences (NBIX) stake by 2,650% in Q2 2026, buying an estimated $7.86K and bringing the position to 55 shares worth $9.35K. The position accounts for ﹤0.01% of the portfolio, ranked #516.

Manning & Napier Advisors first reported a position in NBIX in Q4 2025 and has held it in 3 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Manning & Napier Advisors held 55 shares of Neurocrine Biosciences worth $9.35K as of Q2 2026.
  • Manning & Napier Advisors bought 53 Neurocrine Biosciences shares in Q2 2026, an estimated $7.86K.
  • Neurocrine Biosciences made up ﹤0.01% of Manning & Napier Advisors's portfolio in Q2 2026, its #516 holding.
  • Manning & Napier Advisors first reported a position in Neurocrine Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Manning & Napier Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.